Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

20.05.2024

2 Actas Urol Esp (Engl Ed)
1 Am J Clin Exp Urol
1 Asian J Surg
1 bioRxiv
1 BJUI Compass
1 Cancer Res
1 Cancer Sci
1 Cancers (Basel)
2 Clin Cancer Res
1 Curr Opin Urol
1 Curr Pharm Biotechnol
1 Discov Oncol
1 EBioMedicine
3 Eur Urol
4 Eur Urol Oncol
1 FEBS Lett
1 Free Radic Biol Med
1 Front Oncol
1 Indian J Surg Oncol
3 Int J Mol Sci
1 Int J Neurosci
2 Int J Surg
1 Int J Urol
1 Int Urol Nephrol
1 J Clin Med
1 J Med Invest
1 J Natl Compr Canc Netw
1 Lab Chip
1 Lancet Oncol
2 Medicine (Baltimore)
1 Microbiome
2 Minerva Urol Nephrol
1 Mol Biotechnol
1 Mol Med Rep
1 Mol Oncol
1 Scand J Urol
1 Ther Adv Med Oncol
1 Urol Int
1 Urol J
3 Urol Oncol
1 Urologia
1 World J Urol
1 Zhong Nan Da Xue Xue Bao Yi Xue Ban



    Actas Urol Esp (Engl Ed)

  1. OTERO-MURIEL IJ, Jimenez Giraldo S, Garcia-Perdomo HA
    The association between the human papillomavirus (HPV) and the diagnosis of bladder cancer: systematic review and meta-analysis.
    Actas Urol Esp (Engl Ed). 2024 May 9:S2173-5786(24)00062.
    >> Share

  2. CANO VELASCO J, Artero Fullana S, Polanco Pujol L, Lafuente Puentedura A, et al
    Use of Bladder Epicheck(R) in the follow-up of high-risk non-muscle-invasive Bladder cancer: A systematic literature review.
    Actas Urol Esp (Engl Ed). 2024 May 10:S2173-5786(24)00064.
    >> Share


    Am J Clin Exp Urol

  3. GRIFFIN RL, Shuman L, Yamashita H, Wu Q, et al
    The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.
    Am J Clin Exp Urol. 2024;12:88-99.
    >> Share


    Asian J Surg

  4. CHI J, Jiang X, Liu Q, Cui Y, et al
    Elevated expression of SRRM3 in bladder cancer predicts poor prognosis and is associated with immune infiltration.
    Asian J Surg. 2024 May 9:S1015-9584(24)00869.
    >> Share


    bioRxiv

  5. FARKAS AM, Tran MA, Youssef D, Balan S, et al
    Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling.
    bioRxiv [Preprint]. 2024 May 3:2024.04.30.591366. doi: 10.1101/2024.04.30.591366
    >> Share


    BJUI Compass

  6. GUO L, Cid A, Cucci J, Kunkel B, et al
    Acu-URO17 is a highly sensitive and specific bladder cancer biomarker.
    BJUI Compass. 2024;5:497-501.
    >> Share


    Cancer Res

  7. JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al
    NPEPPS Is a Druggable Driver of Platinum Resistance.
    Cancer Res. 2024;84:1699-1718.
    >> Share


    Cancer Sci

  8. WOO HK, Park J, Kim KH, Ku JY, et al
    Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.
    Cancer Sci. 2024;115:1602-1610.
    >> Share


    Cancers (Basel)

  9. SLUSARCZYK A, Garbas K, Pustula P, Zapala L, et al
    Assessing the Predictive Accuracy of EORTC, CUETO and EAU Risk Stratification Models for High-Grade Recurrence and Progression after Bacillus Calmette-Guerin Therapy in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1684.
    >> Share


    Clin Cancer Res

  10. BALASOORIYA ER, Wu Q, Ellis H, Zhen Y, et al
    The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Clin Cancer Res. 2024;30:2181-2192.
    >> Share

  11. MAGUIRE WF, Lee D, Weinstock C, Gao X, et al
    FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:2011-2016.
    >> Share


    Curr Opin Urol

  12. OBIREDDY SR, Lai WF
    Advances in preclinical approaches for intravesical therapy of bladder cancer.
    Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
    >> Share


    Curr Pharm Biotechnol

  13. QIAO X, Xue R, Li S, Li J, et al
    Expression of LASS2 Can be Regulated by Dihydroartemisinin to Regulate Cisplatin Chemosensitivity in Bladder Cancer Cells.
    Curr Pharm Biotechnol. 2024 May 16. doi: 10.2174/0113892010305651240514100129.
    >> Share


    Discov Oncol

  14. TUO Z, Lin Y, Zhang Y, Gao L, et al
    Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.
    Discov Oncol. 2024;15:160.
    >> Share


    EBioMedicine

  15. LIU L, Xu L, Wu D, Zhu Y, et al
    Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer.
    EBioMedicine. 2024;104:105152.
    >> Share


    Eur Urol

  16. ABSOLOM K, Rogers Z, Catto JWF, Bottomley S, et al
    Decision Regret Regarding Treatment Choices 1 Year After a New Diagnosis of Bladder Cancer.
    Eur Urol. 2024 May 11:S0302-2838(24)02346-7. doi: 10.1016/j.eururo.2024.
    >> Share

  17. TILGENER C, Bedke J
    Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Eur Urol. 2024;85:591-592.
    >> Share

  18. ROSENBERG JE, Mamtani R, Sonpavde GP, Loriot Y, et al
    Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
    Eur Urol. 2024;85:574-585.
    >> Share


    Eur Urol Oncol

  19. BENJAMIN DJ, Rezazadeh Kalebasty A, Prasad V
    The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
    Eur Urol Oncol. 2024;7:313-315.
    >> Share

  20. SAAL J, Grunwald V, Bald T, Ritter M, et al
    On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy.
    Eur Urol Oncol. 2024;7:328-331.
    >> Share

  21. MONTORSI F, Rosiello G, Gandaglia G, Salonia A, et al
    Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/1
    Eur Urol Oncol. 2024;7:636.
    >> Share

  22. GUTMANN M, Ertl IE, Herek P, Vician P, et al
    Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.
    Eur Urol Oncol. 2024 May 15:S2588-9311(24)00115.
    >> Share


    FEBS Lett


  23. Retraction: Wang C, Chen Z, Ge Q, Hu J, Li F, Hu J, Xu H, Ye Z, Li LC (2014) Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells. FEBS Letters 588, 4654-4664. https://doi.org/10.1016/j.febslet.2014.10.037.
    FEBS Lett. 2024 May 15. doi: 10.1002/1873-3468.14892.
    >> Share


    Free Radic Biol Med

  24. NAKAYAMA S, Yoda E, Yamashita S, Takamatsu Y, et al
    Knockdown of iPLA(2)gamma enhances cisplatin-induced apoptosis by increasing ROS-dependent peroxidation of mitochondrial phospholipids in bladder cancer cells.
    Free Radic Biol Med. 2024;220:301-311.
    >> Share


    Front Oncol

  25. QIAN L, Zhang Y, Chen H, Pang Y, et al
    The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence.
    Front Oncol. 2024;14:1364702.
    >> Share


    Indian J Surg Oncol

  26. GINIL KUMAR P, Gideon M, Ravi Chandran K, Pullara SK, et al
    Our Experience of OSAKA Regimen (Bladder Preservation) in Patients with Advanced Bladder Cancer.
    Indian J Surg Oncol. 2024;15:264-267.
    >> Share


    Int J Mol Sci

  27. TYAGI P, Hafron J, Kaufman J, Chancellor M, et al
    Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration.
    Int J Mol Sci. 2024;25:4945.
    >> Share

  28. STURM S, Niegisch G, Windolf J, Suschek CV, et al
    Exposure of Bladder Cancer Cells to Blue Light (lambda = 453 nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic Efficiency of Gemcitabine.
    Int J Mol Sci. 2024;25:4868.
    >> Share

  29. DRACHNERIS J, Morkunas M, Fabijonavicius M, Cekauskas A, et al
    Spatial Distribution of Macrophage and Lymphocyte Subtypes within Tumor Microenvironment to Predict Recurrence of Non-Muscle-Invasive Papillary Urothelial Carcinoma after BCG Immunotherapy.
    Int J Mol Sci. 2024;25:4776.
    >> Share


    Int J Neurosci

  30. ZHENG W, Zhang P, Yao C, Tao Y, et al
    The clinical significance of PD-1 expression in patients with bladder cancer without lymph node metastasis: a comparative study with drained lymph nodes and tumor tissues.
    Int J Neurosci. 2024 May 14:1-17. doi: 10.1080/00207454.2024.2356152.
    >> Share


    Int J Surg

  31. LI X, Huang J, Ji P
    Comment on 'Robot-assisted radical cystectomy with intracorporeal urinary diversion: an updated systematic review and meta-analysis of its differential effect on effectiveness and safety'.
    Int J Surg. 2024;110:3114-3115.
    >> Share

  32. LI J, Kong Z, Qi Y, Wang W, et al
    Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning bioinformatics retrospective study.
    Int J Surg. 2024 May 17. doi: 10.1097/JS9.0000000000001516.
    >> Share


    Int J Urol

  33. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    >> Share


    Int Urol Nephrol

  34. DAVID J, Pathak RA
    Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
    Int Urol Nephrol. 2024;56:1937-1938.
    >> Share


    J Clin Med

  35. CONTIERI R, Pichler R, Del Giudice F, Marcq G, et al
    Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory Roundtable and Literature Review.
    J Clin Med. 2024;13:2637.
    >> Share


    J Med Invest

  36. TEMIRCAN Z
    Investigation of Knowledge, Attitudes, and Healthy Lifestyle Behaviors on Bladder Cancer in Turkey.
    J Med Invest. 2024;71.
    >> Share


    J Natl Compr Canc Netw

  37. FLAIG TW, Spiess PE, Abern M, Agarwal N, et al
    Bladder Cancer, Version 3.2024.
    J Natl Compr Canc Netw. 2024;22:216-225.
    >> Share


    Lab Chip

  38. XIN L, Xiao X, Xiao W, Peng R, et al
    Screening for urothelial carcinoma cells in urine based on digital holographic flow cytometry through machine learning and deep learning methods.
    Lab Chip. 2024;24:2736-2746.
    >> Share


    Lancet Oncol

  39. NECCHI A, Roumiguie M, Kamat AM, Shore ND, et al
    Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
    Lancet Oncol. 2024 May 10:S1470-2045(24)00178.
    >> Share


    Medicine (Baltimore)

  40. EKICI M, Demir E, Aydin C, Caglayan MS, et al
    Can the use of antithrombotic drugs be a predictive factor in the early diagnosis of bladder cancer?: A single-center analysis.
    Medicine (Baltimore). 2024;103:e38228.
    >> Share

  41. QIU Y, Jiang Z, Zhang J
    Causal effects of BMI, waist circumference, and body fat percentage on the risk of bladder cancer: A Mendelian randomization study.
    Medicine (Baltimore). 2024;103:e38231.
    >> Share


    Microbiome

  42. THEN CK, Paillas S, Moomin A, Misheva MD, et al
    Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity.
    Microbiome. 2024;12:89.
    >> Share


    Minerva Urol Nephrol

  43. ZAWKY M, Elsayed A, Awadallah A, Abdelhalim A, et al
    The impact of purified protein derivative prior to intravesical bacillus Calmette-Guerin for the treatment of patients with non-muscle invasive bladder cancer.
    Minerva Urol Nephrol. 2024 May 17. doi: 10.23736/S2724-6051.23.05515.
    >> Share

  44. PALERMO M, D'Elia C, Trenti E, Comploj E, et al
    Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck(R) as a diagnostic tool in upper urinary tract tumor.
    Minerva Urol Nephrol. 2024;76:195-202.
    >> Share


    Mol Biotechnol

  45. WANG Z, Zhang J, Luo L, Zhang C, et al
    Nucleoporin 93 Regulates Cancer Cell Growth and Stemness in Bladder Cancer via Wnt/beta-Catenin Signaling.
    Mol Biotechnol. 2024 May 14. doi: 10.1007/s12033-024-01184.
    >> Share


    Mol Med Rep

  46. LIAO G, Chen F, Zhong J, Jiang X, et al
    [Retracted] MicroRNA?539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF?1R.
    Mol Med Rep. 2024;30:116.
    >> Share


    Mol Oncol

  47. PAN YC, Chu PY, Lin CC, Hsieh CY, et al
    Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.
    Mol Oncol. 2024 May 15. doi: 10.1002/1878-0261.13659.
    >> Share


    Scand J Urol

  48. SCILIPOTI P, Liedberg F, Garmo H, Wilberg Orrason A, et al
    Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostat-ectomy. A nationwide population-based study.
    Scand J Urol. 2024;59:98-103.
    >> Share


    Ther Adv Med Oncol

  49. LI DX, Yu QX, Wu RC, Wang J, et al
    Efficiency of bladder-sparing strategies for bladder cancer: an umbrella review.
    Ther Adv Med Oncol. 2024;16:17588359241249068.
    >> Share


    Urol Int

  50. CHO HJ, Chung HS, Hwang EC, Jung SI, et al
    Music from noise-canceling headphones is beneficial against anxiety in male bladder cancer patients undergoing follow-up cystoscopy: A prospective randomized trial.
    Urol Int. 2024 May 10. doi: 10.1159/000539312.
    >> Share


    Urol J

  51. TANG Z, Can L, Xuan S, Chen L, et al
    Unveiling the Etiology of Urological Tumors: A Systematic Review of Mendelian Randomization Applications in Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer.
    Urol J. 2024 May 11. doi: 10.22037/uj.v21i.7970.
    >> Share


    Urol Oncol

  52. MAHLOW J, Gupta S
    Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance.
    Urol Oncol. 2024;42:193-202.
    >> Share

  53. OLAH C, Kubik A, Matrai P, Engh MA, et al
    Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies.
    Urol Oncol. 2024;42:221.
    >> Share

  54. WANG Y, Song Y, Peng Y, Han S, et al
    Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis.
    Urol Oncol. 2024 May 9:S1078-1439(24)00431-9. doi: 10.1016/j.urolonc.2024.
    >> Share


    Urologia

  55. SERRETTA V
    BCG and bladder cancer. Forty-eight years after Morales report.
    Urologia. 2024 May 17:3915603241252909. doi: 10.1177/03915603241252909.
    >> Share


    World J Urol

  56. BEN-DAVID R, Tillu N, Alerasool P, Bieber C, et al
    Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols.
    World J Urol. 2024;42:315.
    >> Share


    Zhong Nan Da Xue Xue Bao Yi Xue Ban

  57. LI R, Ning Y, Yuan Y, Yang X, et al
    Molecular mechanisms of ferroptosis and its effects on bladder cancer.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49:286-295.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016